DNA topoisomerase II: A primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy

https://doi.org/10.1016/0163-7258(87)90054-4Get rights and content

Abstract

Based on the weight of evidence accrued in the past eight years, there is little question that the nuclear enzyme, topoisomerase II, serves as a common intracellular target for the cytotoxic effect of drugs of widely varying structure. The enzyme appears to be unique as a chemotherapy target in that it is recruited into a lethal process under the influence of drug. Its role contrasts sharply with other more classical chemotherapy targets, such as dihydrofolate reductase, whose activity must be successfully inhibited for the expression of cytotoxicity. Resistance to inhibitors of this enzyme frequently results from marked elevations in intracellular enzyme content. In contrast, the presence of topoisomerase is required for drug effect, and, in general, the greater the cellular content of the enzyme, the more sensitive the cell will be to these agents. However, important issues remain unresolved. The biochemical events that are initiated by cleavable complex formation and result in cell death must be more fully defined. It is likely a better understanding of the drug-enzyme interaction will be required for rational drug development. Finally, those aspects of the drug-topoisomerase interaction that confer therapeutic selectivity and/or clinical resistance are of paramount importance if the phenomenon is ever to be fully exploited.

References (103)

  • J.B. Johnston et al.

    Comparison of DNA scission and cytotoxicity produced by adriamycin and 5-iminodaunorubicin in human colon carcinoma cells

    Biochem. Pharmacol.

    (1983)
  • K. Kirkegaard et al.

    Bacterial DNA topoisomerase I can relax positively supercoiled DNA containing a single-stranded loop

    J. mol. Biol.

    (1985)
  • E.B. Kmiec et al.

    The positive transcription factor of the 55 RNA gene induces a 55 DNA-specific gyration in Xenopus oocyte extracts

    Cell

    (1985)
  • L.F. Liu et al.

    Type II DNA topoisomerases: Enzymes that can unknot a topologically knotted DNA molecule via a reversible double strand break

    Cell

    (1980)
  • L.F. Liu et al.

    Cleavage of DNA by mammalian DNA topoisomerase II

    J. biol Chem.

    (1983)
  • A. Minocha et al.

    Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26

    Biochem. biophys. Res. Commun.

    (1984)
  • R. Miskimins et al.

    Epidermal growth factor-induced topoisomerase(s)

    Exp. Cell Res.

    (1983)
  • H. Noguchi et al.

    Rapid incorporation of label from ribonucleoside diposphates into DNA by cell-free high molecular weight fraction from animal cell nuclei

    Cell

    (1983)
  • N. Osheroff et al.

    DNA topoisomerase II from Drosophila Melanogaster

    J. biol. Chem.

    (1983)
  • Y. Pommier et al.

    Absence of a requirement for long-range DNA torsional strain in the production of protein-associated DNA strand breaks in isolated mammalian cell nuclei by the DNA intercalating agent 4′-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA)

    Biochem. Pharmacol.

    (1984)
  • J.-F. Riou et al.

    In vivo stimulation by antitumor drugs of the topoisomerase II induced cleavage sites in c-myc protooncogene

    Biochem. biophys. Res. Comm.

    (1986)
  • W.E. Ross et al.

    DNA double-stranded breaks in mammalian cells after exposure to intercalating agents

    Biochim. Biophys. Acta

    (1981)
  • W.E. Ross et al.

    Repair of deoxyribonucleic acid lesions caused by adriamycin and ellipticine

    Biochem. Pharmacol.

    (1982)
  • W.E. Ross et al.

    Protein-associated DNA breaks in cells treated with adriamycin or ellipticine

    Biochim. Biophys. Acta

    (1978)
  • W.E. Ross et al.

    Qualitative and quantitative aspects of intercalator-induced DNA strand breaks

    Biochim. Biophys. Acta

    (1979)
  • W.E. Ross et al.

    Relationship between cytotoxicity and DNA strand breakage produced by adriamycin and other intercalating agents

    Int. J. Radiat. Oncol. Biol. Phys.

    (1979)
  • T. Rowe et al.

    Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage

    Biochem. Pharmacol.

    (1985)
  • M. Ryoji et al.

    Chromatin assembly in xenopus oocytes: In vivo studies

    Cell

    (1984)
  • G. Taudou et al.

    DNA topoisomerase activities in concanavalin A-stimulated lymphocytes

    FEBS Lett.

    (1984)
  • K.M. Tewey et al.

    Intercalative antitumor drugs interfere with the breakage-reunion of mammalian DNA topoisomerase II

    J. biol. Chem.

    (1984)
  • J.V. Tricoli et al.

    DNA topoisomerase I and II activities during cell proliferation and the cell cycle in cultured mouse embryo fibroblast (C3H 10T1/2) cells

    Exp. Cell Res.

    (1985)
  • Y.C. Tse et al.

    HMG17 protein facilitates the DNA catenation reaction catalyzed by DNA topoisomerases

    Arch. Biochem. Biophys.

    (1984)
  • H. Waldes et al.

    The interaction of adriamycin with nuclear DNA: Evidence for a drug induced compaction of isolated chromatin

    Biochem. biophys. Res. Comm.

    (1981)
  • L.A. Zwelling et al.

    DNA-repair deficiencies do not affect intercalator-induced cytotoxicity of DNA scission in human cells

    Mutat. Res.

    (1982)
  • P. Ackerman et al.

    Phosphorylation of DNA topisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro

  • A.M. Arnold et al.

    Interaction of VP-16-213 with DNA repair antagonists

    Br. J. Cancer

    (1981)
  • M. Berrios et al.

    In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction

  • G.T. Bowden et al.

    Molecular pharmacology of the anthracycline drug 9,10-anthracenedicarboxaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (Cl 216,942)

    Cancer Res.

    (1982)
  • P.O. Brown et al.

    Catenation and knotting of duplex DNA by type I topoisomerases: A mechanistic parallel with type II topoisomerases

  • L. Brox et al.

    N-trifluoroacetyladriamycin-14-valerate and adriamycin-induced DNA damage in the RPMI-6410 human lymphoblastoid cell line

    Can. J. Biochem.

    (1980)
  • J.-Y. Charcosset et al.

    Effects of 9-OH-ellipticine on cell survival, macromolecular syntheses, and cell cycle progression in sensitive and resistant Chinese hamster lung cells

    Cancer Res.

    (1985)
  • N.R. Cozzarelli

    DNA gyrase and the supercoiling of DNA

    Science

    (1980)
  • M.K. Darby et al.

    Inhibition of calf thymus type II DNA topoisomerase by poly(ADP-ribosylation)

    E.M.B.O. J.

    (1985)
  • S. DiNardo et al.

    DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication

  • C.S. Downes et al.

    Novobiocin inhibition of DNA excision repair may occur through effects on mitochondrial structure and ATP metabolism, not on repair topoisomerases

    Carcinogenesis

    (1985)
  • B. Drewinko et al.

    Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213

    Cancer Treat. Rep.

    (1976)
  • W.C. Earnshaw et al.

    Localization of topoisomerase II in mitotic chromosomes

    J. Cell Biol.

    (1985)
  • W.C. Earnshaw et al.

    Topoisomerase II is a structural component of mitotic chromosome scaffoldsf

    J. Cell Biol.

    (1985)
  • C. Edwards et al.

    Heterogeneity in cellular topoisomerase II content and epipodophyllotoxin sensitivity

    Clin. Res.

    (1986)
  • E. Estey et al.

    Hypersensitivity of mitotic cells to topoisomerase II (topo II)-mediated DNA cleavage

  • Cited by (0)

    View full text